Wave Life Sciences

WVE

Market cap $2.61B

Adrian Rawcliffe disposed of 42,000 shares for a total transaction value of ~$630,000 on Dec. 8, 2025. This transaction was derivative-based, involving the exercise and immediate sale of options; all activity was through direct ownership with no indirect entities involved.

Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026

Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.

In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.

A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely what transpired with Wave Life Sciences (NASDAQ:WVE), the RNA-focused drug developer that astonished Wall Street with data so unexpectedly robust that it reshaped the company's future in just a few hours.

Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.

The golden cross is a highly accurate and bullish technical signal that investors can use to find stocks that can make good momentum trades. A golden cross pattern forms when a stock's 50-day moving average crosses above its 200-day moving average.

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.